These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 7763091)

  • 21. Do antihistone autoantibodies reflect disease activity in linear scleroderma?
    el-Azhary RA; Aponte CC; Nelson AM
    Arch Dermatol; 2004 Jun; 140(6):759-60. PubMed ID: 15210477
    [No Abstract]   [Full Text] [Related]  

  • 22. Antihistone antibodies in patients with localized scleroderma.
    Sato S; Ihn H; Soma Y; Igarashi A; Tamaki T; Kikuchi K; Ishibashi Y; Takehara K
    Arthritis Rheum; 1993 Aug; 36(8):1137-41. PubMed ID: 8343189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-phosphatidylserine-prothrombin complex antibodies in patients with localized scleroderma.
    Hasegawa M; Fujimoto M; Hayakawa I; Matsushita T; Nishijima C; Yamazaki M; Takehara K; Sato S
    Clin Exp Rheumatol; 2006; 24(1):19-24. PubMed ID: 16539814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies to the heat-shock protein hsp73 in localized scleroderma.
    Fujimoto M; Sato S; Ihn H; Takehara K
    Arch Dermatol Res; 1995; 287(6):581-5. PubMed ID: 7487146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-cardiolipin antibodies and other immunological disorders in patients with systemic scleroderma].
    Speranskiĭ AI; Riazantseva TA; Guseva NG; Melkumova KL; Ivanova SM
    Revmatologiia (Mosk); 1990; (3):11-4. PubMed ID: 2098888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihistone antibodies in scleroderma.
    Parodi A; Drosera M; Barbieri L; Rebora A
    Dermatology; 1995; 191(1):16-8. PubMed ID: 8589476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma.
    Zillikens D; Blum C; Dummer R; Hartmann AA; Burg G
    Dermatology; 1992; 184(3):233-4. PubMed ID: 1392125
    [No Abstract]   [Full Text] [Related]  

  • 29. Elevated soluble CD23 levels in the sera from patients with localized scleroderma.
    Sato S; Fujimoto M; Kikuchi K; Ihn H; Tamaki K; Takehara K
    Arch Dermatol Res; 1996 Feb; 288(2):74-8. PubMed ID: 8932584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-U1RNP antibodies in patients with localized scieroderma.
    Yamane K; Ihn H; Kubo M; Kuwana M; Asano Y; Yazawa N; Tamaki K
    Arch Dermatol Res; 2001 Sep; 293(9):455-9. PubMed ID: 11758788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of liver function tests in scleroderma patients.
    Salem GI; Abdulrahman AA
    Rheumatol Int; 2012 Aug; 32(8):2371-5. PubMed ID: 21644046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases.
    Matsushita T; Hasegawa M; Matsushita Y; Echigo T; Wayaku T; Horikawa M; Ogawa F; Takehara K; Sato S
    Exp Dermatol; 2007 Feb; 16(2):87-93. PubMed ID: 17222220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration.
    Kahaleh MB; LeRoy EC
    Ann Intern Med; 1989 Mar; 110(6):446-50. PubMed ID: 2784042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma endothelin and the aminoterminal propeptide of type III procollagen (PIIINP) in systemic sclerosis.
    Zachariae H; Heickendorff L; Bjerring P; Halkier-Sørensen L; Søndergaard K
    Acta Derm Venereol; 1994 Sep; 74(5):368-70. PubMed ID: 7817674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma.
    Arnett FC; Tan FK; Uziel Y; Laxer RM; Krafchik BR; Antohi S; Bona C
    Arthritis Rheum; 1999 Dec; 42(12):2656-9. PubMed ID: 10616014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoantibodies to HMG-17 nucleosomal protein in patients with scleroderma.
    Vlachoyiannopoulos PG; Boumba VA; Tzioufas AG; Seferiadis C; Tsolas O; Moutsopoulos HM
    J Autoimmun; 1994 Apr; 7(2):193-201. PubMed ID: 8037838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
    Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S
    Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
    Hayakawa I; Hasegawa M; Takehara K; Sato S
    Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis.
    Sato S; Ihn H; Kikuchi K; Takehara K
    Arthritis Rheum; 1994 Mar; 37(3):391-4. PubMed ID: 8129794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.